| 摘要 |
<P>PROBLEM TO BE SOLVED: To solve problems that antibodies binding to a cancer-specific marker and having reduced immunogenicity when administered to a human are required, further antibodies selectively killing tumor cells by delivering a toxin or an immunostimulative component to the cancer specific marker, for example, as a fused protein or an immune conjugate, are also required in this technical field. <P>SOLUTION: A recombinant KS antibody is provided. In the antibody, an amino acid sequence defining one or more framework regions and/or complementarity determining areas is modified to reduce immunogenicity of the antibody. <P>COPYRIGHT: (C)2009,JPO&INPIT |
